The Role of the Methyltransferase METTL3 in Prostate Cancer: a Potential Therapeutic Target

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Jan 3

PMID 38166703

Authors

Xuming Zhou

Keqiang Chai

Hezhen Zhu

Cong Luo

Xiaofeng Zou

Junrong Zou

Guoxi Zhang

Affiliations

Soon will be listed here.

Abstract

The incidence of prostate cancer (PCa), the most prevalent malignancy, is currently at the forefront. RNA modification is a subfield of the booming field of epigenetics. To date, more than 170 types of RNA modifications have been described, and N6-methyladenosine (m6A) is the most abundant and well-characterized internal modification of mRNAs involved in various aspects of cancer progression. METTL3, the first identified key methyltransferase, regulates human mRNA and non-coding RNA expression in an m6A-dependent manner. This review elucidates the biological function and role of METTL3 in PCa and discusses the implications of METTL3 as a potential therapeutic target for future research directions and clinical applications.

Citing Articles

MicroRNA155 in non-small cell lung cancer: a potential therapeutic target.

Wei X, Xiong X, Chen Z, Chen B, Zhang C, Zhang W Front Oncol. 2025; 15:1517995.

PMID: 39963112 PMC: 11830606. DOI: 10.3389/fonc.2025.1517995.

Portrait of WWP1: the current state in human cancer.

Lei J, Chen J, Yu W, Wu Q, Jing S, Tang Y Front Cell Dev Biol. 2025; 12:1516613.

PMID: 39949609 PMC: 11821962. DOI: 10.3389/fcell.2024.1516613.

Clinician's Guide to Epitranscriptomics: An Example of N-Methyladenosine (mA) RNA Modification and Cancer.

Kvolik Pavic A, conkas J, Mumlek I, Zubcic V, Ozretic P Life (Basel). 2024; 14(10).

PMID: 39459530 PMC: 11508930. DOI: 10.3390/life14101230.

Role of N‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).

Pan J, Tong F, Ren N, Ren L, Yang Y, Gao F Oncol Rep. 2024; 51(6).

PMID: 38757383 PMC: 11110010. DOI: 10.3892/or.2024.8747.

References

Knuckles P, Lence T, Haussmann I, Jacob D, Kreim N, Carl S . Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the mA machinery component Wtap/Fl(2)d. Genes Dev. 2018; 32(5-6):415-429. PMC: 5900714. DOI: 10.1101/gad.309146.117. View

Lei Q, Jiao J, Xin L, Chang C, Wang S, Gao J . NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell. 2006; 9(5):367-78. DOI: 10.1016/j.ccr.2006.03.031. View

Liu N, Pan T . Probing RNA Modification Status at Single-Nucleotide Resolution in Total RNA. Methods Enzymol. 2015; 560:149-59. DOI: 10.1016/bs.mie.2015.03.005. View

Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K . AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017; 7:42271. PMC: 5304225. DOI: 10.1038/srep42271. View

Li P, Shi Y, Gao D, Xu H, Zou Y, Wang Z . ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner. Int J Biol Sci. 2022; 18(16):6145-6162. PMC: 9682537. DOI: 10.7150/ijbs.75063. View

Petri B, Klinge C . m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer. J Mol Endocrinol. 2022; 70(2). PMC: 9790079. DOI: 10.1530/JME-22-0110. View

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

Boriack-Sjodin P, Ribich S, Copeland R . RNA-modifying proteins as anticancer drug targets. Nat Rev Drug Discov. 2018; 17(6):435-453. DOI: 10.1038/nrd.2018.71. View

10.

Mao C, Huang C, Hu Z, Qu S . Transcription factor CASZ1 increases an oncogenic transcriptional process in tumorigenesis and progression of glioma cells. MedComm (2020). 2022; 3(4):e182. PMC: 9583698. DOI: 10.1002/mco2.182. View

11.

Boccaletto P, Stefaniak F, Ray A, Cappannini A, Mukherjee S, Purta E . MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 2021; 50(D1):D231-D235. PMC: 8728126. DOI: 10.1093/nar/gkab1083. View

12.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

13.

Wang P, Doxtader K, Nam Y . Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell. 2016; 63(2):306-317. PMC: 4958592. DOI: 10.1016/j.molcel.2016.05.041. View

14.

Cai C, He H, Chen S, Coleman I, Wang H, Fang Z . Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011; 20(4):457-71. PMC: 3225024. DOI: 10.1016/j.ccr.2011.09.001. View

15.

Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J . Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics. 2021; 11(16):7640-7657. PMC: 8315076. DOI: 10.7150/thno.61178. View

16.

Du C, Lv C, Feng Y, Yu S . Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res. 2020; 39(1):223. PMC: 7576758. DOI: 10.1186/s13046-020-01735-3. View

17.

Carvalho T, Cardoso H, Figueira M, Vaz C, Socorro S . The peculiarities of cancer cell metabolism: A route to metastasization and a target for therapy. Eur J Med Chem. 2019; 171:343-363. DOI: 10.1016/j.ejmech.2019.03.053. View

18.

Rucci N, Angelucci A . Prostate cancer and bone: the elective affinities. Biomed Res Int. 2014; 2014:167035. PMC: 4058249. DOI: 10.1155/2014/167035. View

19.

Lin Y, Wei X, Jian Z, Zhang X . METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma. Cancer Med. 2020; 9(8):2859-2867. PMC: 7163109. DOI: 10.1002/cam4.2918. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View